Jupiros-A Capsule contains a combination of Rosuvastatin 10 mg and Aspirin 75 mg, formulated to provide dual therapeutic benefits in cardiovascular risk management. Rosuvastatin, a potent HMG-CoA reductase inhibitor, effectively lowers low-density lipoprotein cholesterol (LDL-C) and triglycerides while modestly increasing high-density lipoprotein cholesterol (HDL-C), thereby reducing the risk of atherosclerotic cardiovascular disease. Aspirin, an antiplatelet agent, irreversibly inhibits cyclooxygenase-1 (COX-1), leading to decreased thromboxane A2 production and subsequent inhibition of platelet aggregation, which helps prevent thrombus formation. The combined action of these agents makes Jupiros-A Capsule suitable for patients requiring lipid-lowering therapy alongside antiplatelet prophylaxis, particularly those with a history of coronary artery disease, stroke, or peripheral arterial disease. The recommended dosage should be individualized based on patient risk factors, clinical response, and tolerability. Caution is advised in patients with hepatic or renal impairment, bleeding disorders, or hypersensitivity to either component. Regular monitoring of lipid profiles, liver function tests, and signs of bleeding is recommended during therapy. Jupiros-A Capsule should be used under medical supervision to optimize cardiovascular outcomes and minimize adverse effects.